Stereotactic Ablative Radiotherapy Using CALYPSO ® Extracranial Tracking for Intrafractional Tumor Motion Management-A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study

(1) Background: The aim of this study was to evaluate the efficacy and safety of SABR for LAPC using Calypso® Extracranial Tracking for intrafractional, fiducial-based motion management, to present this motion management technique, as there are yet no published data on usage of Calypso® during SABR...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2022-05, Vol.14 (11), p.2688
Main Authors: Kaučić, Hrvoje, Kosmina, Domagoj, Schwarz, Dragan, Mack, Andreas, Šobat, Hrvoje, Čehobašić, Adlan, Leipold, Vanda, Andrašek, Iva, Avdičević, Asmir, Mlinarić, Mihaela
Format: Article
Language:English
Subjects:
Abdomen
Antimitotic agents
Antineoplastic agents
Cancer therapies
Care and treatment
Complications
Diagnosis
Dosage and administration
Drug dosages
Magnetic resonance imaging
Management
Medical prognosis
Metastasis
Pancreatic cancer
Patient outcomes
Patients
Radiation therapy
Radiosurgery
Surgery
Survival
Toxicity
Transponders
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:(1) Background: The aim of this study was to evaluate the efficacy and safety of SABR for LAPC using Calypso® Extracranial Tracking for intrafractional, fiducial-based motion management, to present this motion management technique, as there are yet no published data on usage of Calypso® during SABR for LAPC, and to report on our clinical outcomes. (2) Methods: Fifty-four patients were treated with SABR in one, three, or five fractions, receiving median BED10 = 112.5 Gy. Thirty-eight patients received systemic treatment. End points were OS, FFLP, PFS, and toxicity. Actuarial survival analysis and univariate analysis were investigated. (3) Results: Median follow-up was 20 months. Median OS was 24 months. One-year FFLP and one-year OS were 100% and 90.7%, respectively. Median PFS was 18 months, and one-year PFS was 72.2%. Twenty-five patients (46.3%) were alive at the time of analysis, and both median FU and OS for this subgroup were 26 months. No acute/late toxicity > G2 was reported. (4) Conclusions: SABR for LAPC using Calypso® presented as an effective and safe treatment and could be a promising local therapeutic option with very acceptable toxicity, either as a single treatment or in a multimodality regimen. Dose escalation to the tumor combined with systemic treatment could yield better clinical outcomes.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers14112688